Roche to Develop Two Novel RNA-targeted Programs from Ionis for CNS Diseases
Roche will gain exclusive worldwide rights to develop, manufacture, and commercialize Ionis’ investigational RNA-based therapeutic candidates for Alzheimer's and Huntington's disease.
Novartis Completes Sandoz Spin-off
Spinning off Sandoz allows Novartis to focus on the areas of cardiovascular, immunology, renal and metabolic, and oncology.
Millions Raised for the Development of Precision Oncology Platform
Orakl Oncology has raised funds to develop its precision oncology platform and accelerate drug development.
Sanofi and Janssen Sign Agreement for Phase III Extraintestinal Pathogenic E. coli Vaccine Candidate
Sanofi is set to pay $175 million upfront to Janssen, followed by development and commercial milestones.
UK Poised to Lead Global Delivery of Next-Gen mRNA Medicines
The BioIndustry Association reports that with a strong foundation in research and development in mRNA the United Kingdom will be a major player in this rapidly growing industry.
Kyowa Kirin Set to Acquire Orchard Therapeutics for $477.6 million
The Japanese biotech company plans to make good use of Orchard’s portfolio, furthering its goal of providing life-changing medical care through cell and gene therapy.
Advent International, Warburg Pincus Complete $4.25 Billion Acquisition of Baxter’s BioPharma Solutions Business
The newly established business under Advent International and Warburg Pincus will be named Simtra BioPharma Solutions.
Sartorius and SPARTA Biodiscovery Partner on Novel Nanoparticle Analysis Platform
Under the partnership, Sartorius will leverage SPARTA Biodiscovery’s technology to accelerate development of nanoparticles used for drug delivery.
BARDA Awards Gritstone bio $433 Million Contract for Phase IIb Study of Next-Gen COVID-19 Vaccine
The contract is part of US Department of Health and Human Services’ ‘Project NextGen’ initiative, aimed at pushing forward new and stronger COVID-19 vaccines and therapies.
MilliporeSigma Opens Two New GMP Manufacturing Sites in Germany for mRNA Production
With the two new GMP-grade mRNA manufacturing sites in Germany, MilliporeSigma can now offer fully integrated mRNA services.
Losing Weight, Gaining Value
Novo Nordisk’s obesity treatment has been so successful the company is now top of the ‘value pile’ in Europe.
Torx Software and CDD Vault to Collaborate on Global Drug Discovery
The collaboration will provide easy access and transfer between data in Torx and CDD Vault, upping the efficiency of the small-molecule discovery process.
Genentech Forms Collaboration with PeptiDream for Peptide-Radioisotope Drug Conjugates
Under a new pact, Genentech and PeptiDream will collaborate to discover and develop novel peptide-radioisotope drug conjugates.
Alexion Completes Purchase and License Agreement of Rare Disease Gene Therapy Portfolio from Pfizer
The AstraZeneca rare disease group hopes to use these new gene therapy programs to bolster its work on genomic medicine.
Genentech Partners with Orionis Biosciences to Discover and Develop Molecular Glue Class Medicines
Under the collaboration, Orionis will receive $47 million upfront to leverage its Allo-Glue platform to discover small-molecule monovalent glues.
CN Bio and LifeNet Health LifeSciences Partner to Supply Pre-Validated Cells
CN Bio and LifeNet Health LifeSciences have teamed up to provide direct access to a portfolio of highly characterized hepatic cells for the creation of advanced liver-on-a-chip assays.
Illumina Establishes New Center in India to Expand Genomics Capabilities
Illumina’s new solutions center in Bengaluru, India, will expand access to genomics in the country.
Optibrium Acquires BioPharmics
Optibrium announced on Aug. 31, 2023 the acquisition of BioPharmics to further expand the 3D drug design and modelling offering and to focus on research and development and application science.
Novo Nordisk Acquires Embark Biotech
Novo Nordisk receives the full rights to develop and commercialize the lead program.
Zevra Therapeutics to Acquire Acer Therapeutics
Both companies have a focus to developing and commercializing treatments for rare diseases with a strong focus on patients and supporting communities with little to no existing therapeutic options.
Harnessing the Power of Oncolytic Viruses
Tumour-infiltrating lymphocyte (TIL) therapies offer a new route to target cancer.
Billions of Reasons to be Buoyant
Pharma's ability to continually reinvent itself will be critical in growing future business operations.
Bristol Myers Squibb Joins Cellares Program Focused on Automated Cell Therapy Manufacturing as Cellares is Launched as First IDMO
Bristol Myers Squibb has joined Cellares’ Technology Adoption Partnership program just as Cellares launches operations as an integrated development and manufacturing organization.
Unpacking Amgen v. Sanofi
Exploring the state of pharma patents following the Supreme Court’s Amgen v. Sanofi decision.
Sirio Europe Announces New Softgel Formulations
The new products aim to aid consumers with menopause and eye health-related issues.
Examining Microbubble Cell Separation Techniques with Brandon McNaughton
Brandon McNaughton, founder and CEO of Akadeum Life Sciences, discusses his start-up’s unique microbubble separation technology.
Three-Way Collaboration Between Rentschler Biopharma, CGT Catapult, and Refeyn Aims to Improve PAT for Gene Therapy Manufacturing
Rentschler Biopharma, CGT Catapult, and Refeyn aim to use automated and digital technologies to improve AAV manufacturing for gene therapies.
Danaher to Acquire Abcam in $5.7 Billion Deal
Danaher intends to acquire Abcam, a provider of life sciences assays and reagents, for $5.7 billion.
Royalty Pharma Places $500 Million Bet on Ferring Gene Therapy
Royalty Pharma agreed to spend up to $500 million for a 5.1 to 8% royalty on net sales of Ferring’s gene therapy adstiladrin (nadofaragene firadenovec-vcng).
Chiesi Global Rare Diseases and Aliada Therapeutics Partner to Advance Blood-Brain Barrier-Crossing Platform Technology for Drug Delivery
With this agreement, Chiesi Global Rare Diseases will co-develop drug delivery systems with Aliada Therapeutics for large-molecule therapeutics that can cross the blood-brain barrier.
